Anaerobic Bacterial Spore Therapeutics and their Manufacture

肠道微生物组是一种具有药理活性的组织，控制感染、炎症、受体信号、激素分泌和中枢神经系统信号。这些事件对患者的健康和福祉有重大影响(《自然》杂志特别评论，2012年6月)。肠道微生物群在健康和疾病中的重要性现在得到了广泛的认识，导致研究、开发和制药投资激增，这种基于活微生物的新疗法可以治疗慢性肠道相关疾病。梭状芽孢杆菌是人类大肠中最普遍的一类微生物。Chain Biotech利用其在这些细菌方面的独特专业知识，开发了一种治疗炎症性肠病的新型活生物疗法。该产品已在临床前测试中得到验证，我们现在正在寻找一家能够生产用于临床试验的孢子的制造合作伙伴。英国没有这样的设施，这个项目试图解决这个瓶颈。更具体地说，合作伙伴将确定在东南地区为Chain和其他中小企业微生物组和生物技术公司建立定制孢子制造厂的成本和经济可行性。

"The gut microbiome is a pharmacologically active tissue controlling infection, inflammation, receptor signalling, hormone secretion and central nervous system signalling. These events have significant impacts on patient health and wellbeing (Nature Special Review, June 2012). The importance of the gut microbiome in both health and disease is now widely recognised resulting in an explosion in research, development and pharma investment in new therapeutics, based on live microbes, that can treat chronic gut related diseases.Clostridia are the most prevalent class of microbes in the human large intestine. CHAIN Biotech capitalises on its unique expertise with these bacteria to develop a novel live biotherapeutic for treating inflammatory bowel disease. This product has been validated in pre-clinical tests and we now seek a manufacturing partner that can produce spores for clinical trials. No such facility exists in the UK and this project seeks to address this bottleneck. More specifically, the partners will determine the costs and economic feasibility to build a bespoke spore manufacturing plant in the South East for CHAIN and other SME microbiome and biotech companies."